清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Temozolomide in aggressive pituitary tumours and pituitary carcinomas

替莫唑胺 医学 肿瘤科 卡培他滨 内科学 放射治疗 拉帕蒂尼 化疗 癌症 结直肠癌 乳腺癌 曲妥珠单抗
作者
Ann McCormack
出处
期刊:Best Practice & Research Clinical Endocrinology & Metabolism [Elsevier]
卷期号:36 (6): 101713-101713 被引量:8
标识
DOI:10.1016/j.beem.2022.101713
摘要

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC) has significantly improved following the increasing use of temozolomide (TMZ) since the first reports of response in 2006. TMZ was established as first line chemotherapy for APT/PC in the 2018 ESE guidelines on the management of APT/PC. There is no controversy over its use as salvage therapy however there is increasing interest in exploring TMZ use earlier in the treatment algorithm for APT/PC. Overall response rates as reported in systematic reviews are around 40% but stable disease in another 25% illustrates the clinical effectiveness of TMZ. Response is higher among functional compared to non-functional tumours. Where maximal radiation thresholds have not been reached in a patient, combination radiotherapy and TMZ appears more effective. Whether combination TMZ and capecitabine (CAPTEM) offers increased benefit remains uncertain particularly given added toxicity. O6-methyl guanine DNA methyl transferase (MGMT) status is important in determining response to treatment, although examination via immunohistochemistry versus PCR-based promoter-methylation analysis remains somewhat controversial. Optimal duration of TMZ treatment has still not been determined although longer treatment courses have been associated with increased progression-free survival. Treatment options following disease progression after TMZ remain unclear but include a second course of TMZ, immunotherapy and targeted oncological agents such as bevacizumab and lapatinib as well as peptide receptor radionuclide treatment (PRRT). An experienced pituitary multidisciplinary team is essential to all management decisions in patients with APT/PC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mahua完成签到 ,获得积分10
14秒前
btbu2015发布了新的文献求助30
17秒前
sunflowers完成签到 ,获得积分10
19秒前
IVY1300完成签到 ,获得积分10
28秒前
56秒前
自信小丛完成签到 ,获得积分10
59秒前
doreen完成签到 ,获得积分10
1分钟前
YUNUN发布了新的文献求助10
2分钟前
SciGPT应助YUNUN采纳,获得10
2分钟前
马帅完成签到 ,获得积分10
3分钟前
平淡的小懒虫完成签到 ,获得积分10
4分钟前
高贵梦秋完成签到,获得积分10
4分钟前
D&L完成签到,获得积分10
4分钟前
cyskdsn完成签到,获得积分20
5分钟前
xwl9955完成签到 ,获得积分10
5分钟前
猪仔5号完成签到 ,获得积分10
6分钟前
iberis完成签到 ,获得积分10
6分钟前
zz完成签到 ,获得积分10
7分钟前
7分钟前
会飞的猪完成签到 ,获得积分10
7分钟前
7分钟前
Lee_Ice完成签到,获得积分10
8分钟前
Wang完成签到 ,获得积分20
8分钟前
Lee_Ice发布了新的文献求助10
8分钟前
爱心完成签到 ,获得积分10
9分钟前
li8888lili8888完成签到 ,获得积分10
9分钟前
NexusExplorer应助Lee_Ice采纳,获得10
9分钟前
爆米花应助武雨寒采纳,获得10
9分钟前
9分钟前
9分钟前
btbu2015发布了新的文献求助30
9分钟前
武雨寒完成签到,获得积分20
10分钟前
武雨寒发布了新的文献求助10
10分钟前
上善若水完成签到 ,获得积分10
10分钟前
10分钟前
武雨寒发布了新的文献求助10
10分钟前
juan完成签到 ,获得积分10
11分钟前
微笑芒果完成签到 ,获得积分10
11分钟前
12分钟前
慕青应助科研通管家采纳,获得10
12分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545838
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600226
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557